SENORESNSESenores Pharmaceuticals LimitedMediumPositive
Announced Fri, 3 Apr · 20:01 IST

Senores Pharmaceuticals Limited has informed the Exchange regarding media release

Marquee Jv AnnouncedStrategic Transactions View source PDF

SENORES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.9%1-day move
₹785.00
prior close
₹800.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4-0.3-0.9-0.6-1.9-0.1+2.3+4.5+7.0+13.6+17.1+18.2+28.0+72.3
Up moveDown movePending
AI summary

Senores Pharmaceuticals' US subsidiary (Senores Pharmaceuticals, Inc.) has entered into a strategic partnership by forming a Joint Venture entity called Amerisyn, LLC. The formal Operating Agreement was executed on April 2, 2026. This JV positions the group to supply its pharmaceutical products to the U.S. Federal Government, veterans affairs, and military supply contracts. The management expects this partnership to be a significant driver of growth and a substantial contributor to international business volumes. The company currently has 46 ANDAs approved and operates three formulation manufacturing facilities across US, India and Canada.

Likely market impact

The JV opens access to a high-entry-barrier market in U.S. government procurement, which could drive meaningful revenue growth from a new customer segment with long-term contract potential.